Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.63 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20583752 | 0.85 | IDO1 (0.52) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL3480016 | 0.84 | RIPK1 (0.78) | RIPK1 | |
| SCHEMBL20782032 | 0.84 | RIPK1 (0.47) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL3640937 | 0.83 | IDO1 (0.55) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL10725568 | 0.83 | IDO1 (0.50) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL808941 | 0.83 | IDO1 (0.50) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL2951310 | 0.83 | IDO1 (0.50) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL20428030 | 0.83 | IDO1 (0.50) | RIPK1IDO1TAAR1CHRM2CHRM1 | |
| SCHEMBL17750072 | 0.83 | IDO1 (0.50) | IDO1TAAR1CHRM2CHRM1CA1 | |
| SCHEMBL10190891 | 0.82 | RIPK1 (0.49) | RIPK1CA1CA2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348475-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 | TRANSLATIONAL GENOMICS RES INST (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-21 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2005100301-A1 | 2-ARYLOXYETHYL GLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| US-4288638-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1981-09-08 | — | — | US | disclosed |
| US-4236029-A | Process for the synthesis of 2,4-dinitro-6-t-butyl-3-methylanisole, referred to as musk ambrette | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | RIPK1 1913/4885IDO1 3923/4885TAAR1 4670/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | RIPK1 214/4885IDO1 3700/4885TAAR1 3699/4885 |
| US-20230348475-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 | CDK7, CDK8, CDKL4 | RIPK1 1419/4885IDO1 2630/4885TAAR1 3692/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | RIPK1 486/4885IDO1 1979/4885TAAR1 4194/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | RIPK1 3349/4885IDO1 627/4885TAAR1 2374/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | RIPK1 1215/4885IDO1 3280/4885TAAR1 4669/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | RIPK1 581/4885IDO1 3799/4885TAAR1 3127/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | RIPK1 2459/4885IDO1 3963/4885TAAR1 643/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | RIPK1 354/4885IDO1 4746/4885TAAR1 4425/4885 |
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | RIPK1 4870/4885IDO1 813/4885TAAR1 66/4885 |
| US-20080200459-A1 | TETRAHYDROQUINOLINE CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | RIPK1 1387/4885IDO1 2050/4885TAAR1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.